Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence

Overview of attention for article published in Therapeutics and Clinical Risk Management, May 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 45 Mendeley

Summary X Facebook Dimensions citations

So far, Dimensions has found 18 publications that cite this research output.

18

The most recent citing publications are shown below. View all 18 publications that cite this research output on Dimensions.

Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab

Article in TH Open (April 2024)

Activated Factor X delivered by Adeno-Associated virus significantly inhibited bleeding and alleviated hemophilia A/B arthropathy in hemophilia mice

Preprint in Research Square (January 2024)

Generation and pathogenicity of autoantibodies associated to thrombosis and hemostasis

Article in Exploration of Immunology (January 2024)